Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia

Amylyx Pharmaceuticals plans to file for FDA approval of avexitide, a GLP-1 receptor blocker for post-bariatric hypoglycemia, after a positive Phase 3 trial demonstrating significant reduction in severe hypoglycemic episodes. The drug targets a rare but sizeable market in the US with around 160,000 patients and potential peak global sales of $1.7 billion.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.